# ADVANCE: An Observational Study To Determine Bortezomib Safety and Effectiveness at First Relapse After Participation In First Line HOVON-49/50 Clinical Studies.

> **NCT00440479** · — · COMPLETED · sponsor: **Janssen-Cilag B.V.** · enrollment: 11 (actual)

## Conditions studied

- Multiple Myeloma
- Hematological Neoplasms

## Interventions

- **DRUG:** Bortezomib

## Key facts

- **NCT ID:** NCT00440479
- **Lead sponsor:** Janssen-Cilag B.V.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2006-09
- **Primary completion:** 2011-01
- **Final completion:** 2011-01
- **Target enrollment:** 11 (ACTUAL)
- **Last updated:** 2015-04-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00440479

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00440479, "ADVANCE: An Observational Study To Determine Bortezomib Safety and Effectiveness at First Relapse After Participation In First Line HOVON-49/50 Clinical Studies.". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00440479. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*